162 related articles for article (PubMed ID: 26293519)
21. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.
Moore BR; Benjamin JM; Salman S; Griffin S; Ginny E; Page-Sharp M; Robinson LJ; Siba P; Batty KT; Mueller I; Davis TM
Antimicrob Agents Chemother; 2014 Oct; 58(10):5784-94. PubMed ID: 25049242
[TBL] [Abstract][Full Text] [Related]
22. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
[TBL] [Abstract][Full Text] [Related]
23. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
24. The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine.
Zang M; Zhu F; Zhao L; Yang A; Li X; Liu H; Xing J
Malar J; 2014 Dec; 13():478. PubMed ID: 25476790
[TBL] [Abstract][Full Text] [Related]
25. A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.
Crockett J; Critchley D; Tayo B; Berwaerts J; Morrison G
Epilepsia; 2020 Feb; 61(2):267-277. PubMed ID: 32012251
[TBL] [Abstract][Full Text] [Related]
26. Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV.
Banda CG; Nkosi D; Allen E; Workman L; Madanitsa M; Chirwa M; Kapulula M; Muyaya S; Munharo S; Wiesner L; Phiri KS; Mwapasa V; Ter Kuile FO; Maartens G; Barnes KI
J Antimicrob Chemother; 2022 May; 77(6):1733-1737. PubMed ID: 35288747
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Pharmacokinetics and Ex Vivo Antimalarial Activities of Artesunate-Amodiaquine and Artemisinin-Piperaquine in Healthy Volunteers for Preselection Malaria Therapy.
Quang NN; Chavchich M; Anh CX; Birrell GW; van Breda K; Travers T; Rowcliffe K; Edstein MD
Am J Trop Med Hyg; 2018 Jul; 99(1):65-72. PubMed ID: 29741150
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.
Tarning J; Lindegardh N; Lwin KM; Annerberg A; Kiricharoen L; Ashley E; White NJ; Nosten F; Day NP
Antimicrob Agents Chemother; 2014; 58(4):2052-8. PubMed ID: 24449770
[TBL] [Abstract][Full Text] [Related]
29. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
30. Effects of food on the pharmacokinetics of ponatinib in healthy subjects.
Narasimhan NI; Dorer DJ; Niland K; Haluska F; Sonnichsen D
J Clin Pharm Ther; 2013 Dec; 38(6):440-4. PubMed ID: 23888935
[TBL] [Abstract][Full Text] [Related]
31. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
[TBL] [Abstract][Full Text] [Related]
32. Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults.
Qin H; Tan Y; Diao L; Hui AM; Wu Z; Zhou Y; Sun J; Xiang X; Qiu J; Hu W
Drugs R D; 2023 Dec; 23(4):465-473. PubMed ID: 37934354
[TBL] [Abstract][Full Text] [Related]
33. Progress in the development of piperaquine combinations for the treatment of malaria.
D'alessandro U
Curr Opin Infect Dis; 2009 Dec; 22(6):588-92. PubMed ID: 19773652
[TBL] [Abstract][Full Text] [Related]
34. Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Kajubi R; Huang L; Jagannathan P; Chamankhah N; Were M; Ruel T; Koss CA; Kakuru A; Mwebaza N; Kamya M; Havlir D; Dorsey G; Rosenthal PJ; Aweeka FT
Clin Pharmacol Ther; 2017 Sep; 102(3):520-528. PubMed ID: 28187497
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.
Sambol NC; Yan L; Creek DJ; McCormack SA; Arinaitwe E; Bigira V; Wanzira H; Kakuru A; Tappero JW; Lindegardh N; Tarning J; Nosten F; Aweeka FT; Parikh S
Clin Pharmacol Ther; 2015 Jul; 98(1):87-95. PubMed ID: 25732044
[TBL] [Abstract][Full Text] [Related]
36. Piperaquine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperaquine.
Millat-Martínez P; Salman S; Moore BR; Baro B; Page-Sharp M; Batty KT; Robinson LJ; Pomat W; Karunajeewa H; Laman M; Manning L; Mitjà O; Bassat Q
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0018522. PubMed ID: 35862743
[TBL] [Abstract][Full Text] [Related]
37. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
38. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL
Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
Creek DJ; Bigira V; McCormack S; Arinaitwe E; Wanzira H; Kakuru A; Tappero JW; Sandison TG; Lindegardh N; Nosten F; Aweeka FT; Parikh S
J Infect Dis; 2013 Jun; 207(11):1646-54. PubMed ID: 23447696
[TBL] [Abstract][Full Text] [Related]
40. Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
Banda CG; Nkosi D; Allen E; Workman L; Madanitsa M; Chirwa M; Kapulula M; Muyaya S; Munharo S; Tarning J; Phiri KS; Mwapasa V; Ter Kuile FO; Maartens G; Barnes KI
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0058422. PubMed ID: 36374096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
